Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

In the VITamin D and OmegA-3 TriaL (VITAL), there were no differences in 2-yr changes in areal BMD (aBMD) at the spine, hip, or whole body in 771 U.S. participants (687 with follow-up data) randomized to supplemental vitamin D3 (2000 IU/d) vs placebo.

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study protocol.

Study protocol

Describes planned methods and is not evidence that the planned study has reported results.

Meta-analysis unclear · Double-blind reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

The parent VITAL trial was a 2 × 2 factorial, double-blinded, randomized, placebo-controlled trial that investigated the effects of supplemental vitamin D3 and/or marine omega-3 fatty acid, compared to placebo, on the primary prevention of cancer and cardiovascular disease in 25 871 U.S.

Source: Methods.

men aged ≥50 yr and women aged ≥55 yr., Over a median treatment duration of 5.3 yr, neither supplemental vitamin D nor marine omega-3 fatty acid reduced incidence of cancer or cardiovascular disease in the overall cohort, although there were certain subgroups who benefited.

Source: Methods.

This trial protocol has been detailed previously.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Investigating the interrelationship of vitamin K and vitamin D status on bone density: results from the VITamin D and OmegA-3 TriaL

Study protocol · JBMR Plus · 2026

Original publication title

Investigating the interrelationship of vitamin K and vitamin D status on bone density: results from the VITamin D and OmegA-3 TriaL

Sharon H Chou; Sarah L Booth; Nancy R Cook; Eunjung Kim; Gregory Kotler; Xueyan Fu; Julie E Buring; JoAnn E Manson; Meryl S LeBoff

© The Author(s) 2026. Published by Oxford University Press on behalf of the American Society for Bone and Mineral Research.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Abstract

Sufficient intake of both vitamin D and K may be necessary for bone health. Although the synthesis of osteocalcin (OC) is stimulated by vitamin D, OC needs to be carboxylated, or activated, by vitamin K to deposit calcium into bone. In the VITamin D and OmegA-3 TriaL (VITAL), there were no differences in 2-yr changes in areal BMD (aBMD) at the spine, hip, or whole body in 771 U.S. participants (687 with follow-up data) randomized to supplemental vitamin D3 (2000 IU/d) vs placebo.

In this ancillary study, we investigated whether baseline vitamin K status was associated with changes in bone density and structure and whether baseline vitamin K status modified the effects of supplemental vitamin D on aBMD changes. Higher baseline vitamin K status, as assessed by blood levels of phylloquinone, percent undercarboxylated OC, and dephosphorylated undercarboxylated matrix Gla protein, was not associated with favorable 2-yr changes in aBMD at the spine, hip, or whole body as assessed by DXA, trabecular bone score, or volumetric BMD (vBMD) and bone architecture outcomes at the radius and tibia as assessed by peripheral QCT.

The effects of supplemental vitamin D on aBMD were not modified by baseline measures of vitamin K. In VITAL, higher vitamin K status, even when accompanied by supplemental vitamin D, did not prevent bone loss.

Clinical Trial Registration No.: NCT04573946 (ClinicalTrials.gov).

Authors’ abstract

Abstract

Sufficient intake of both vitamin D and K may be necessary for bone health. Although the synthesis of osteocalcin (OC) is stimulated by vitamin D, OC needs to be carboxylated, or activated, by vitamin K to deposit calcium into bone. In the VITamin D and OmegA-3 TriaL (VITAL), there were no differences in 2-yr changes in areal BMD (aBMD) at the spine, hip, or whole body in 771 U.S. participants (687 with follow-up data) randomized to supplemental vitamin D3 (2000 IU/d) vs placebo.

In this ancillary study, we investigated whether baseline vitamin K status was associated with changes in bone density and structure and whether baseline vitamin K status modified the effects of supplemental vitamin D on aBMD changes. Higher baseline vitamin K status, as assessed by blood levels of phylloquinone, percent undercarboxylated OC, and dephosphorylated undercarboxylated matrix Gla protein, was not associated with favorable 2-yr changes in aBMD at the spine, hip, or whole body as assessed by DXA, trabecular bone score, or volumetric BMD (vBMD) and bone architecture outcomes at the radius and tibia as assessed by peripheral QCT.

The effects of supplemental vitamin D on aBMD were not modified by baseline measures of vitamin K. In VITAL, higher vitamin K status, even when accompanied by supplemental vitamin D, did not prevent bone loss.

Clinical Trial Registration No.: NCT04573946 (ClinicalTrials.gov).

Publication and source details

Original title: Investigating the interrelationship of vitamin K and vitamin D status on bone density: results from the VITamin D and OmegA-3 TriaL

Sharon H Chou; Sarah L Booth; Nancy R Cook; Eunjung Kim; Gregory Kotler; Xueyan Fu; Julie E Buring; JoAnn E Manson; Meryl S LeBoff

JBMR Plus · 2026

Corresponding author: Sharon H. Chou, Division of Endocrinology, Diabetes and Hypertension, Department of Medicine Brigham and Women’s Hospital, Harvard Medical School, 221 Longwood Avenue, Boston, MA 02115, United States (shchou@bwh.harvard.edu).© The Author(s) 2026. Published by Oxford University Press on behalf of the American Society for Bone and Mineral Research.2026https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. USDA Agricultural Research Service under Cooperative Agreement 58-8050-3-003 Harvard Catalyst Clinical and Translational Science Center UL1TR001102 NCCIH10.13039/100008460 R01AT011729 NCI and NHLBI R01CA138962 NIAMS/NIH R01 AR059775R01 AR070854R01 AR060574

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-09T20:18:20.799444+00:00

DOI: 10.1093/jbmrpl/ziag110 · PMC13411269